Program
larsucosterol
Also written as “DUR-928 30 mg”, “DUR-928 90 mg” and “DUR-928”.
Its studies are mostly in Hepatitis, Alcoholic · Hepatitis · Cholangitis, Sclerosing · Psoriasis, led by Bausch Health Companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bausch Health Companies | 61 open or running | phase 3since Feb 19, 2026 | Jan 3, 2018 | Nov 2027phase 3 · NCT07428538 |
Also a collaborator on its studies: therapeutics-inc.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 3, 2018First study: phase 2 study in Cholangitis, SclerosingFirst studyNCT03394781 · 5 enrolled · United States
- Feb 1, 2018Phase 2 study in Hepatitis, AlcoholicNCT03432260 · 19 enrolled · United States
- Feb 5, 2019Phase 2 study in Plaque PsoriasisNCT03837743 · 25 enrolled · United States
- Jun 23, 2020Phase 2 study in SARS-CoV-2NCT04447404 · 2 enrolled · United States
- Sep 18, 2020Phase 2 study in Hepatitis, AlcoholicNCT04563026 · 307 enrolled · United States, Australia, Austria and more
- Feb 19, 2026Phase 3 study in HepatitisPhase 3 reachedNCT07428538 · 350 planned · United States
Ahead
- Nov 2027Primary completion: phase 3 study in HepatitisNCT07428538
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07428538Hepatitis · United States | 3 | Recruiting | Nov 2027 | 350 |
| NCT04563026Hepatitis, Alcoholic · United States, Australia, Austria and more | 2 | Completed | Sep 6, 2023 | 307 |
| NCT04447404SARS-CoV-2 · United States | 2 | Terminated | Mar 4, 2021 | 2 |
| NCT03837743Plaque Psoriasis · United States | 2 | Completed | Nov 11, 2019 | 25 |
| NCT03432260Hepatitis, Alcoholic · United States | 2 | Completed | Sep 9, 2019 | 19 |
| NCT03394781Cholangitis, Sclerosing · United States | 2 | Terminated | Jan 31, 2019 | 5 |
How it is read
Names in the registry
- “DUR-928 30 mg”, 2 entries
- “DUR-928 90 mg”, 2 entries
- “DUR-928”, 2 entries
- “Larsucosterol”, 1 entry
- “DUR-928 150 mg”, 1 entry
Conditions, from the studies’ own filings
- Hepatitis, Alcoholic, 2 studies
- Hepatitis, 1 study
- Cholangitis, Sclerosing, 1 study
- Psoriasis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.